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Abstract 
Introduction: Eradication of Pseudomonas aeruginosa (P.a.) in patients with cystic fibrosis (CF) is possible if it is initiated in the 
early course of infection. Therefore, the detection of P.a. as early as possible is an important goal of care. Regular determination 
of antibodies to P.a. antigens in serum may be useful in patients who have not yet been infected or were infected intermittently. 
The aim of the present study was to assess the concentrations of antibodies to selected antigens of P. aeruginosa in the serum 
of children with CF and with known status of P.a. infection.
Material and methods: The study was performed in 111 CF patients (27 not infected with P. aeruginosa, 29 with intermittent 
infection and 55 with chronic infection). The concentrations of IgG antibodies to the alkaline protease (AP), elastase (ELA) and 
exotoxin A (Exo-A) were measured. The increased concentration of antibodies was defined as exceeding 500 units (according 
to the manufacturer). The results of antibodies assessment were analysed according to previous infection status and the results 
of present culture. 
Results: At the time of the study, P.a. was cultured from sputum of 57 patients: 9 out of 29 (31%) with intermittent infection, and 
48 out of 55 (87%) with chronic infection. Increased concentrations of antibodies to one or more P.a. antigens were found in 60 
patients, and to all three types of antigens in 30 patients. Increased serum antibody concentration was found significantly more 
often in the patients with chronic P.a. infection compared to those with intermittent infection (82% vs. 35%, p = 0.0001). In the 
patients with chronic P.a. infection (especially with mucoid type), serum antibody concentrations were significantly higher than in 
other patients. Higher concentrations of antibodies were also found in the patients with positive result of P.a. culture at the time 
of the study, compared to those with negative culture. In 19% of patients not infected with P.a., increased serum antibodies to at 
least one P.a. antigen were found. The clinical significance of such findings is unclear and needs further investigation. 
Conclusions: In the present study, the increased serum concentrations of IgG antibodies to P. aeruginosa antigens (AP, ELA and 
Exo-A) were found most often in the patients with chronic P.a. infection and in those in whom P.a. (especially mucoid type) was 
cultured at the time of the study. The clinical significance of the elevated antipseudomonal antibodies level in 19% of the patients 
never infected with P.a. is unclear and needs further investigation. 
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Streszczenie
Wstęp: Eradykacja Pseudomonas aeruginosa (P.a.) u pacjentów z mukowiscydozą jest możliwa, jeśli zostanie rozpoczęta na 
wczesnym etapie zakażenia. Z tego powodu wykrycie P.a. stanowi ważny element opieki nad chorymi. Oznaczanie przeciwciał 
dla antygenów P.a. w surowicy może być użyteczne u pacjentów, którzy dotychczas nie byli zakażeni Pseudomonas aeruginosa 
lub byli zakażeni w sposób przerywany.
Celem badania była ocena stężenia przeciwciał dla wybranych antygenów Pseudomonas aeruginosa w surowicy chorych na 
mukowiscydozę (CF, cystic fibrosis), ze znaną historią zakażenia. 
Materiał i metody: Badania wykonano u 111 pacjentów (27 dotychczas nie zakażonych, 29 z okresowym zakażeniem i 55 prze-
wlekle zakażonych), u których oznaczano stężenia przeciwciał IgG dla alkalicznej proteazy (AP), elastazy (ELA) i egzotoksyny A 
(Exo-A) metodą immunoenzymatyczną. Za podwyższone stężenie przeciwciał uznawano wartość powyżej 500 jednostek produ-
centa.
Wyniki zestawiono z aktualnym badaniem mikrobiologicznym plwociny oraz z wywiadem dotyczącym zakażenia P.a. 
Wyniki: Aktualny wzrost P.a. z plwociny stwierdzono u 57 chorych: 9 spośród 29 (31%) z okresowym zakażeniem i 48 spośród 55 
(87%) z zakażeniem przewlekłym. U 60 chorych stwierdzono podwyższone stężenie przeciwciał dla co najmniej jednego antygenu 
P.a., u 30 – dla wszystkich badanych antygenów. 
Odsetek chorych z podwyższonym surowiczym stężeniem przeciwciał był istotnie wyższy wśród chorych przewlekle zakażonych 
w porównaniu z zakażonymi okresowo (82% v. 35%, p = 0,0001). U chorych przewlekle zakażonych P.a. (zwłaszcza szczepem 
śluzowym) stężenia przeciwciał były wyższe niż w pozostałych grupach. 
U chorych aktualnie zakażonych P.a. stwierdzono istotnie wyższe stężenie przeciwciał antypseudomonalnych w porównaniu 
z chorymi, u których aktualnie nie stwierdzano wzrostu P.a. 
U 19% badanych z dotychczas i aktualnie ujemnymi wynikami mikrobiologicznego badania w kierunku obecności P.a uzyskano 
dodatnie wyniki oznaczenia przeciwciał dla co najmniej 1 antygenu tej bakterii. Zjawisko to ma niejasne znaczenie kliniczne 
i wymaga dalszej obserwacji.
Wnioski: W badanej grupie chorych na mukowiscydozę odpowiedź immunologiczna na zakażenie P.a. zależała w większości 
przypadków od czasu i intensywności zakażenia. Stężenie przeciwciał było również związane z aktualną obecnością szczepu P.a. 
w hodowli – najwyższe stężenie przeciwciał obserwowano wśród aktualnie zakażonych typem śluzowym P.a.. Znaczenie kliniczne 
przeciwciał przeciwko P.a. u 19% chorych dotychczas nie zakażonych tym patogenem jest niejasne i wymaga dalszych badań. 
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Introduction
Cystic fibrosis (CF) is a genetically determi-
ned, multiorgan, autosomal recessive disease. 
It cannot be cured (similarly as other genetic 
diseases), but knowledge about its pathogene-
sis, the course of the disease, early detection of 
complications and the improvement of treatment 
methods have significantly extended survival 
time and ameliorated its quality. 
Cystic fibrosis develops due to mutation of the 
gene encoding the CFTR protein (cystic fibrosis 
transmembrane conductance regulator), which 
is found in the apical membrane of the surface of 
epithelial cells. The effect of inappropriate func-
tioning of CFTR is dehydration and the condensa-
tion of secretion in excretory ducts of the exocrine 
glands. Excessive density of secretion causes distur-
bances in the transport through the excretory ducts, 
with its progressive damage. The epithelium of the 
airways is particularly exposed to the development 
of bacterial infections, whereas the impairment of 
ciliary clearance hinders the elimination of path-
ogens. At the initial stage of the disease, the airways 
are the most frequently infected with Haemophilus 
influenzae and Staphylococcus aureus. As the dise-
ase progresses, Pseudomonas aeruginosa infections 
develop. Over time, P.a. is the dominating pathogen 
with a negative influence on the respiratory system. 
At the beginning, non-mucoid, in vitro susceptible 
to antibiotics P. aeruginosa strains are usually cul-
tured [1, 2]. Together with the progression of the 
disease, the frequency of isolation of the mucoid 
form of P. aeruginosa increases. 
Eradication of P.a. in CF patients is possible 
if it is initiated early in the course of infection 
[2, 3]. Therefore, early detection of P.a. is an 
important target in monitoring CF patients. The 
application of serological methods may be useful 
in early detection of infection [4, 5]. 
The objective of the study was to evaluate the 
concentration of antibodies to selected antigens 
of P.a. (alkaline protease, elastase and exotoxin A) 
in serum of cystic fibrosis patients with known 
history of infection, and to compare the obtained 
results with microbiological tests.
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Material and methods
The analysis included 111 CF patients dia-
gnosed and treated at the Institute of Tuberculosis 
and Lung Diseases in Rabka Zdrój. Depending 
on the results of the previous sputum or swab 
cultures for P. aeruginosa taken at least every 3 
months during the previous 12 months, patients 
were divided into three groups, according to the 
definition by Lee et al. [6]:
1. Group 1. Free of infection: P a. never cultured 
from sputum or swab.
2. Group 2. Intermittent infection: the growth 
of P.a. in less than 50% of samples.
3. Group 3. Chronic infection: the growth of P.a. 
in more than 50% of samples.
The concentrations of IgG antibodies to selec-
ted P.a. antigens [alkaline protease (AP), elastase 
(ELA), exotoxin A (Exo-A)] were examined using 
enzyme-linked immuno ELISA assay, based on 
sets from the Mediagnost GmbH, Germany. Values 
exceeding 500 arbitrary units were assumed as 
a positive concentration (according to the ma-
nufacturer).
Material from the airways (sputum collected 
from older children and adults, or swabs from 
the throat of younger children) were analysed 
according to the manufacturer’s guidelines. In 
patients with exacerbations, material was taken 
prior to the start of antibiotic therapy. In patients 
treated with inhaled antibiotics, material was 
taken at least 12 hours after the last dose. Media 
produced by the company Graso were used. The 
cultured P. aeruginosa strains were identified with 
the help of ID 32 GN strips, BioMerieux Polska, 
using miniAPI apparatus. 
Results
The mean age of patients with CF was 11.2 
± 6.0 years, range from 3 months to 28.1 years. 
The mean age in the study groups was as follows:
1. Group 1 (27 patients) — 7.9 ± 4.8 years; 
range: 0.3–18.1 years.
2. Group 2 (29 patients) — 10.4 ± 4.0 years; 
range: 0.9–18.4 years.
3. Group 3 (55 patients) — 13.1 ± 4.3 years; 
range: 0.3–20.0 years.
Table 1 shows the relationship between 
the current results of P. a. culture and the data 
concerning the type of infection. The frequen-
cy of currently positive cultures of P. a. and its 
mucoid morphotype increased together with 
the infection chronicity. Among patients with 
intermittent infection (Group 2), the growth of 
P. a. was found in 9/29 patients (31%), including 
the growth of mucoid strain in 2 patients (7%), 
non-mucoid in 6 patients (21%) and both types 
in 1 patient (3%). Among patients with chronic 
infection (Group 3), the growth of P.a. was found 
in 48/55 patients (87%), including the growth 
of mucoid strain in 15 patients (27%), non- 
-mucoid in 13 patients (24%) and both types in 
20 patients (36%). 
In 60 patients, elevated concentration of IgG 
antibodies was found (> 500 U) for at least one 
P. aeruginosa antigen, and in 30 patients — for 
all examined antigens. Positive results were ob-
tained in 40 patients (36%) for alkaline protease 
(AP), in 46 patients (41%) for elastase (ELA), and 
in 47 patients (42%) for exotoxin A (Exo-A). For 
AP antigen, the frequency of elevated antibody 
concentration was 14% among intermittently 
infected patients (Group 2) and 62% among 
chronically infected patients (Group 3). Similar 
dependencies were found for the remaining anti-
gens: for ELA — 17% and 71% in Groups 2 and 3, 
respectively, and for Exo-A — 24% and 65%, 
respectively (Table 2). 
Elevated antipseudomonal antibody con-
centrations were also found in serum from the 
patients free of P.a. infection — for AP and ELA 
Table 1.  Actual results of culture according to chronicity of Pseudomonas aeruginosa infection in 111 children with cystic 
fibrosis
Type of infection Number 
of patients
P.a.
negative culture
No (%)
P.a.
positive culture
No (%)
Nonmucoid P.a.
No
Mucoid P.a.
No
Both types  
of P.a.
No 
No infection 27 27 (100) 0 (0) 0 0 0
Periodic infection 29 20 (69) 9 (31) 6 2 1
Chronic infection 55 7 (13) 48 (87) 13 15 20
Total 111 54 (49) 57 (51) 19 17 21
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Table 2.  The frequency of detection of antibodies against Pseudomonas aeruginosa according to chronicity of infection. 
Antibodies to the alkaline protease (AP), elastase (ELA) and exotoxin A (Exo-A)
Type of infection Number  
of patients
Increased concentration of antibodies 
No (%) ≥ 1
No (%)
AP 
(+)
No (%)
ELA 
(+)
No (%)
Exo-A 
(+)
No (%)
All types
 No (%)
No infection 27 22 (81) 5 (19) 2 (7) 2 (7) 4 (15) 1 (4)
Periodic infection 29 19 (65) 10 (35) 4 (14) 5 (17) 7 (24) 3 (10)
Chronic infection 55 10 (18) 45 (82) 34 (62) 39 (71) 36 (65) 26 (47)
Total 111 51 (46) 60 (54) 40 (36) 46 (41) 47 (42) 30 (27)
(+) — positive result
Table 3.  The concentration of antibodies against Pseudomonas aeruginosa according to chronicity of infection. Antibodies 
to the alkaline protease (AP), elastase (ELA) and exotoxin A (Exo-A)
Type of infection Number 
of patients 
AP
x ± SD
ELA
x ± SD
Exo-A
x ± SD
No infection 27  70 ± 221  136 ± 288  305 ± 902
Periodic infection 29  280 ± 807  527 ± 1446  519 ± 910
Chronic infection 55  1359 ± 1283*  2483 ± 2494*  1622 ± 1559*
*p < 0.001 compared to groups with periodic infection and without infection 
antigens — in 7% of patients for each antigen, for 
Exo-A — in 15% of patients, and for at least one 
antigen — in 5 patients (19%) (Table 2). 
Normal antibodies concentration (< 500 U) 
was found in 50 patients: including 81% of pa-
tients free of infection to date, in 65% of patients 
with intermittent infection, and in 18% of chro-
nically infected patients. 
Table 3 presents the absolute values of antip-
seudomonal antibodies depending on infection 
chronicity. Significantly higher concentrations 
of the examined antibodies were observed in 
chronically infected patients in comparison to 
other groups (p < 0.001). 
In 57 patients with currently P.a.-positive 
culture, elevated levels of antibodies to AP, ELA 
and Exo-A antigens were found in 91%, 87% and 
85% of patients, respectively. 
Table 4 shows antipseudomonal antibody 
concentrations depending on the current growth 
of P.a. from sputum. Significantly higher antibo-
dies concentrations were found in the case of the 
current growth of mucoid type of P. aeruginosa, 
compared to the non-mucoid type of P.a. 
Table 4.  Concentration of antibodies against Pseudomonas aeruginosa according to actual culture results. Antibodies to 
the alkaline protease (AP), elastase (ELA) and exotoxin A (Exo-A)
Current culture result
Number  
of patients
Antibodies concentration
AP ELA Exo-A 
c ± SD c ± SD c ± SD
Negative 54  92 ± 240 216 ± 401 276 ± 670
Only non-mucoid P.a. 19 807 ± 1134# 1316 ± 1998# 774 ± 1001*
Only mucoid P.a 17  1684 ± 1397#^ 2959 ± 2824#^ 2364 ± 1738#^
Wzrost P.a. nieśluzowy + śluzowy
Both types of P.a.
21  1731 ± 1273#^ 3320 ± 2521#^ 2071 ± 1468#^
#p < 0.001 significant difference comparing to the group with negative culture 
*p < 0.05 significant difference comparing to the group with negative culture 
^p < 0.05 significant difference comparing to the group with non-mucoid type of P.a.
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Discussion
In the presented group of children and young 
adults with cystic fibrosis, it was shown that the 
frequency of isolation of P. aeruginosa increases 
together with age, in accordance with data pu-
blished by other authors [4]. 
Negative results of culture in 13% of chro-
nically infected patients with P.a., and in 69% 
of intermittently infected patients, illustrate the 
difficulties concerning culturing methods in the 
examined population. Potential reasons inclu-
de, among others, the problems with obtaining 
material from the lower airways, particularly in 
younger patients (in some of them a pharyngeal 
swab was collected). The other possible cause of 
negative culture in chronically infected patients 
is the growth of P. aeruginosa in the airways in 
the form of biofilm. In such cases the secretion 
includes only single colonies of P.a. that leave 
biofilm [5]. In the present study some patients 
received the therapy with an inhaled antibiotic. 
In such circumstances the material was taken 
at least 12 hours after the last dose, so it was 
unlikely that it influenced the obtained results, 
as the concentration of inhaled antibiotic in the 
secretion decreases rapidly below MIC [7]. 
The main exoproducts of P. aeruginosa are: 
alginate capsule (which acts as an adhesive and 
antiphagocytic factor), pilin (important during 
initial colonisation of the epithelium), adhesins, 
toxins [among others lipopolysaccharide, ente-
rotoxin, exotoxin S (exoenzyme S), exotoxin A 
— the main toxin of P. aeruginosa], hemolysins 
(which degrade surfactant) and proteases (e.g. 
elastase, alkaline protease). The production of 
proteases that decompose fibronectin and expo-
se receptors plays a crucial role in the invasion 
and favours the spread of infection. Moreover, 
elastase decomposes collagen, IgG, IgA and the 
components of the complement, whereas alkaline 
protease degrades fibrin. They both participate in 
inactivation of interferon and TNF [8]. 
Immunologic response to P.a. infection re-
sults in the production of antibodies directed 
against antigens and toxins of the bacteria [4, 6]. 
In the study groups, the increase in the 
prevalence and concentration of IgG antibodies 
to the three antigens (AP, ELA and Exo-A), with 
increasing chronicity of infection by P. aerugi-
nosa, was found. The obtained results confirm 
the possibility of monitoring the response of the 
immune system to P.a. antigens by measuring the 
concentration of antibodies to antigens of the bac-
teria. The highest antibodies concentrations were 
found in patients infected with mucoid strain of 
P. aeruginosa. As mucoid strains appear mostly 
in patients with chronic infection, it suggests the 
role of time (and possibly the intensity) of stimu-
lation with P.a. antigens in provoking immune 
response. Other researchers also showed that in 
CF patients, the response of the immune system 
is greater in the case of infection with mucoid 
phenotype of P.a. These antibodies are not able to 
inhibit bacteria growth, but they participate in the 
development of immune complexes that activate 
specific and non-specific inflammatory defence 
mechanisms of the lungs. Chronic inflammatory 
process is the main cause of destruction, worse-
ning of lung function and developing progressive 
respiratory insufficiency [7, 9]. Therefore, it is 
possible that detection of specific antipseudomo-
nal antibodies in CF may help in the identifica-
tion of patients with aggressive forms of chronic 
infection [10].
In the study group, antipseudomonal anti-
bodies concentration was highest in chronically 
infected patients. However, in 18% of chronically 
infected patients, elevated antibody concentra-
tion was not found. The clinical meaning of this 
finding was unclear, but the possible reasons 
could be corticotherapy in some patients, low 
sensitivity of serological test or the lack of current 
P. aeruginosa growth from sputum. 
In the present study, in 19% of patients, in-
creased concentration of antibodies for at least 
one P. aeruginosa antigen was found — in spite 
of permanently negative results of cultures. This 
finding might be caused by latent or intermit-
tent P.a. infection and requires further clinical 
observation, in particular, repeated cultures of 
material from the airways. 
It should be emphasised that current indi-
cations for P. aeruginosa eradication depend on 
microbiological confirmation of the presence of 
bacteria in the airways. According to current 
knowledge, treatment based only on antibody 
concentration cannot be recommended, but it may 
be an indication for more intensive microbiologi-
cal testing (e.g. verification through culturing the 
material obtained from bronchoscopy) [10–12]. 
West et al. found that in CF patients diagno-
sed through screening tests of newborn infants, 
P. aeruginosa infection of the lungs had occurred 
between the 6th and 12th months [13]. Monitoring 
the titre of anti P.a. antibodies could perhaps faci-
litate recognition and treatment of P.a. infections 
in such population. 
Serological diagnosis of P.a. infection in CF 
has been applied in clinical practice in Europe for 
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many years. In the USA and Canada it is used for 
scientific purposes only [14]. Lowering of antibo-
dy titre in response to treatment with tobramycin 
inhalations in patients with early P.a. infection 
has been shown, but in patients with chronic P.a. 
infection the level of antibodies rarely decreased 
in response to antibacterial treatment. 
The results of the present study are in accor-
dance with data of Kappler et al. [1], who used 
the same commercialised sets to determine the 
three serum IgG antibodies against P. aeruginosa 
(AP, ELA and Exo-A). Positive antibody titre was 
indicative for the presence of P. aeruginosa in the 
airways with a sensitivity of 86% and specificity 
of 90%, whereas a negative result indicated lack of 
P. aeruginosa infection with a positive predictive 
value of 97%, (especially in younger children). 
From a clinical perspective, regular determination 
of the serum level of antibodies to P.a. may be 
useful in patients with negative microbiological 
P. aeruginosa status. If the antibody titre rises, 
P. aeruginosa infection is suspected, which sho-
uld lead to intensive microbiological testing and 
a possible eradication treatment. 
The obtained results imply that periodic 
serum antibody determination may be useful in 
CF patients who were to date free of P. aeruginosa 
infection, or who were infected intermittently. 
Conclusions
In the study group of patients with cystic 
fibrosis, immune response to infection with 
P. aeruginosa in the majority of cases depended 
on the time and intensity of infection. In the pa-
tients with chronic P.a. infection, higher antibody 
concentration was found, in comparison with 
intermittently infected patients. 
Anti P.a. antibody concentration was also 
dependent of the current presence of P. aeruginosa 
strain in the culture and its type — the highest 
values were observed in patients currently infec-
ted with mucoid type of P.a. 
Elevated antibody concentration for at least 
one out of three P. aeruginosa antigens was also 
found in 19% of patients free of the pathogen. 
It may imply latent P.a. infection in this group 
of patients and needs further investigation and 
correlation with clinical data. 
Low concentrations of antibodies against 
P. aeruginosa that were found in 18% of patients 
chronically infected with P.a. is an interesting fin-
ding, the interpretation of which is possible only 
in the context of the clinical course of the disease. 
Conflict of interest
The authors declare no conflict of interest.
References:
1. Kappler M., Kraxner A., Reinhardt D. et al. Diagnostic and 
prognostic value of serum antibodies against Pseudomonas 
aeruginosa in cystic fibrosis. Thorax 2006; 61: 684–688.
2. Høiby N., Frederiksen B., Pressler T. Eradication of early Pseudo-
monas aeruginosa infection. J. Cyst. Fibros. 2005; 4: 49–54.
3. Murris-Espin M. Pyocyanique et bronchectasies mucoviscido-
siques et non mucoviscidosiques de l’adulte: de la colonisation 
à l’infection. Rev. Mal. Respir. Actual. 2013; 5: 47–53.
4. Zhanhai Li, Kosorok M.R., Farrell P. M. et al. Children with 
cystic fibrosis Pseudomonas aeruginosa infection and lung 
disease progression in longitudinal development of mucoid 
pseudomonas. JAMA 2005; 293: 5, 581–588. 
5. Moss R.B. Cystic fibrosis: Pathogenesis, pulmonary infection 
and treatment. Clin. Infect. Dis. 1995; 21: 839–851.
6. Lee T.W.R., Brownlee K.G., Conway S.P., et al. Evaluation of 
a new definition for chronic Pseudomonas aeruginosa infec-
tion in cystic fibrosis patients. J. Cyst. Fibros. 2003; 2: 29–34.
7. Sharma A., Krause A., Worgall S. Recent developments for 
Pseudomonas vaccines. Human Vaccines 2011; 7: 999–1011. 
8. Hobby N., Giwercman B., Jensen E.T., et al. Immune response 
in cystic fibrosis — is more always better? Paediatr. Paedol. 
1994; 29: 17–23.
9. Caballero E., Drobnic M.E., Pérez M.T., et al. Anti-Pseudomo-
nas aeruginosa antibody detection in patients with bronchiec-
tasis without cystic fibrosis. Thorax 2001; 56: 669–674.
10. Hoiby N. Antibodies against Pseudomonas aeruginosa in pa-
tients with bronchiectasis: helpful or harmful? Thorax 2001; 
56: 667–668.
11. Pressler T., Karpati F., Granstrom M., et al. Diagnostics signifi-
cance of measurement of specific IgG antibodies to Pseudomo-
nas aeruginosa by three different serological methods. J. Cyst. 
Fibros. 2009; 8: 37–42.
12. Tramper-Stranders G.A., van der Ent C.K., M G Slieker M.G., 
et al. Diagnostic value of serological tests against Pseudomonas 
aeruginosa in a large cystic fibrosis population. Thorax 2006; 
61: 689–693.
13. West S.E., Zeng L., Lee B.L. et al. Respiratory infections with 
Pseudomonas aeruginosa in children with cystic fibrosis: early 
detection by serology and assessment of risk factors. JAMA 
2002; 287: 2958–2967.
14. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and 
management of pulmonary infections in cystic fibrosis. Am. J. 
Respir. Crit. Care Med. 2003; 168: 918–951.
